Get ahead in your career - track and evidence all your medical learning

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment | Key-points-from-the-evidence | Advice | NICE

One large (n=1528), open-label, randomised controlled trial (RCT; ICON7) that assessed the efficacy and safety of bevacizumab 7.5 mg/kg for treating ovarian cancer was identified; quality of life outcomes from this study were also reported separately (Stark et al. 2013). ICON7 found that interim ...
Shared on Wednesday 28th October 2015


Asra Alwandi
Medical Student - St. Georges University, London
Posted about 4 years ago
It's very interesting to read about what different clinical trials have found. I must stress though that the treatments described here are very expensive and it would probably be difficult to use them in the clinical setting.